Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Single Dose Tanimilast (CHF6001) in Liver Impairment
NCT05373953Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- May 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tanimilast in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Maximum Plasma Concentration at 240 hours and Area Under the Curve to Last Timepoint at 240 hours. Started May 2022; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05373953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373953.